A Call for a Rational Polypharmacy Policy: International Insights From Psychiatrists
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Recently, rational polypharmacy approaches have been proposed, regardless of the lower risk and cost of monotherapy. Considering monotherapy as first-line treatment and polypharmacy as rational treatment, a balanced attitude toward polypharmacy is recommended. However, the high prevalence of polypharmacy led the Japanese government to establish a polypharmacy reduction policy. Based on this, the association between the policy and psychiatrists’ attitude toward polypharmacy has been under debate.Methods We developed an original questionnaire about Psychiatrists’ attitudes toward polypharmacy (PAP). We compared the PAP scores with the treatment decision-making in clinical case vignettes. Multiple regression analyses were performed to quantify associations of explanatory variables including policy factors and PAP scores. The anonymous questionnaires were administered to psychiatrists worldwide.Results The study included 347 psychiatrists from 34 countries. Decision-making toward polypharmacy was associated with high PAP scores. Multiple regression analysis revealed that low PAP scores were associated with the policy factor (β=-0.20, p=0.004). The culture in Korea was associated with high PAP scores (β=0.34, p<0.001), whereas the culture in India and Nepal were associated with low scores (β=-0.15, p=0.01, and β=-0.17, p=0.006, respectively).Conclusion Policy on polypharmacy may influence psychiatrists’ decision-making. Thus, policies considering rational polypharmacy should be established.
Abstract
Objective Recently, rational polypharmacy approaches have been proposed, regardless of the lower risk and cost of monotherapy. Considering monotherapy as first-line treatment and polypharmacy as rational treatment, a balanced attitude toward polypharmacy is recommended. However, the high prevalence of polypharmacy led the Japanese government to establish a polypharmacy reduction policy. Based on this, the association between the policy and psychiatrists’ attitude toward polypharmacy has been under debate.Methods We developed an original questionnaire about Psychiatrists’ attitudes toward polypharmacy (PAP). We compared the PAP scores with the treatment decision-making in clinical case vignettes. Multiple regression analyses were performed to quantify associations of explanatory variables including policy factors and PAP scores. The anonymous questionnaires were administered to psychiatrists worldwide.Results The study included 347 psychiatrists from 34 countries. Decision-making toward polypharmacy was associated with high PAP scores. Multiple regression analysis revealed that low PAP scores were associated with the policy factor (β=-0.20, p=0.004). The culture in Korea was associated with high PAP scores (β=0.34, p<0.001), whereas the culture in India and Nepal were associated with low scores (β=-0.15, p=0.01, and β=-0.17, p=0.006, respectively).Conclusion Policy on polypharmacy may influence psychiatrists’ decision-making. Thus, policies considering rational polypharmacy should be established.
참고문헌 (18)
- Möller HJ, "History, background, concepts and current use of comedication and polypharmacy in psychiatry", Int J Neuropsychopharmacol, 17, pp.983~996 (2014)
- Shinfuku N, "Research on Asian Prescription Patterns(REAP) : focusing on data from Japan", Taiwan J Psych, 28, pp.71~85 (2014)
- Yang SY, "Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries : Fourth survey of Research on Asian Prescription Patterns on antipsychotics", Psychiatry Clin Neurosci, 72, pp.572~579 (2018)
- Hirano Y, "Changes in prescription of psychotropic drugs after introduction of polypharmacy reduction policy in Japan based on a largescale claims database", Clin Drug Investig, 39, pp.1077~1092 (2019)
- Kingsbury SJ, "Psychopharmacology : rational and irrational polypharmacy", Psychiatr Serv, 52, pp.1033~1036 (2001)
- Preskorn SH, "Polypharmacy: when is it rational?", J Psychiatr Pract, 13, pp.97~105 (2007)
- Kukreja S, "Polypharmacy in psychiatry : a review", Mens Sana Monogr, 11, pp.82~99 (2013)
- Tiihonen J, "Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia", JAMA Psychiatry, 76, pp.499~507 (2019)
- Ghaemi SN, "Polypharmacy in Psychiatry" (2002), CRC Press
- Nakagami Y, "Revision of road traffic law in Japan and mental health stigma", Psychiatry Clin Neurosci, 73, pp.284~285 (2019)
- Seo DC, "The effect of a smoke-free campus policy on college students’ smoking behaviors and attitudes", Prev Med, 53, pp.347~352 (2011)
- Boyle DCM, "Fast Facts: Religion and Medicine" (2008), Health Press Limited
- Ishigooka J, "Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan : a 6-week, randomized, double-blind, placebo-controlled study", Psychiatry Clin Neurosci, 72, pp.692~700 (2018)
- Correll CU, "Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia : a 6-week randomized, double-blind, placebo-controlled trial", Am J Psychiatry, 172, pp.870~880 (2015)
- Correll CU, "Antipsychotic polypharmacy : a survey study of prescriber attitudes, knowledge and behavior", Schizophr Res, 131, pp.58~62 (2011)
- Kishimoto T, "Antipsychotic polypharmacy : a Japanese survey of prescribers’ attitudes and rationales", Psychiatry Res, 209, pp.406~411 (2013)
- James BO, "Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria : characteristics associated with high reported antipsychotic polypharmacy", Psychiatry Res, 248, pp.134~139 (2017)
- Li L, "Using case vignettes to measure HIV-related stigma among health professionals in China", Int J Epidemiol, 36, pp.178~184 (2007)